Atenção!


O atendimento às questões referentes ao Repositório Institucional será interrompido entre os dias 20 de dezembro de 2025 a 4 de janeiro de 2026.

Pedimos a sua compreensão e aproveitamos para desejar boas festas!

Logo do repositório

Estudo sobre a resistência aos antimicrobianos em bactérias isoladas de pacientes hospitalizados (Botucatu, 1988-1992)

dc.contributor.authorMontelli, Augusto Cezar [UNESP]
dc.contributor.authorWatanabe, Dard S. A. Aoki [UNESP]
dc.contributor.authorMichelin, Lourival Antônio [UNESP]
dc.contributor.authorSadatsune, Terue [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:18:06Z
dc.date.accessioned2014-05-27T11:18:03Z
dc.date.available2014-05-27T11:18:06Z
dc.date.available2014-05-27T11:18:03Z
dc.date.issued1996-09-01
dc.description.abstractSince 1988 to 1992, a study about susceptibility to antimicrobial drugs of bacterias isolated from hospitalized patients was performed. The compared susceptibility to important drugs (ampicilin, cephalothin, cefoxitin, ceftazidime, ceftriaxone, aztreonam, gentamicin, amikacin, peftoxacin, ciprofloxacin, imipenem, oxacillin and vancomicin) was investigated in 1200 strains (300 of each specie) of the prevalent bacterias: E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and S. aureus. Minimal inhibitory concentration (MIC) was determined by agar dilution method, using from 0,05 to 256 mcg of each drug per ml of culture medium (Mueller-Hinton). Ranges of MIC, MIC 50%, MIC 90% and the proportion of resistant strains were determined and permited to know the 4 drugs that were found to be more active against bacterias; the CIM 90% values are: E. coli - aztreonam (0,1 mcg/ml), pefloxacin (0,1), ceftazidime (0,25) and ceftriaxone (0,05); K. pneumoniae - aztreonam (0,25), ceftriaxone (0,25), ceftazidime (0,5) and pefloxacin (2,0); P. aeruginosa - imipenem (4,0), aztreonam (16), ceftazidime (16) and ciprofloxacin (16); S. aureus - vancomicina (1,0), ciprofloxacin (8,0), arnicacina (128) and cephalothin (128 mg/ml). The better in vitro antibacterial activity observed was related to: aztreonam (77-100% of the sensitive strains), ceftazidime (50-99,7%), pefloxacin (73-99,7%), ciprofloxacin(80%), imipenem (93%) and vancomicin (100%).en
dc.description.affiliationDepartamento de Clínica Faculdade Med. de Botucatu - Unesp.
dc.description.affiliationDepto. de Microbiologia e Imunologia Instituto de Biociéncias Campus de Botucatu - Unesp.
dc.description.affiliationUnespDepartamento de Clínica Faculdade Med. de Botucatu - Unesp.
dc.description.affiliationUnespDepto. de Microbiologia e Imunologia Instituto de Biociéncias Campus de Botucatu - Unesp.
dc.format.extent963-969
dc.identifier.citationRevista Brasileira de Medicina, v. 53, n. 9, p. 963-969, 1996.
dc.identifier.issn0034-7264
dc.identifier.issn0015-5454
dc.identifier.scopus2-s2.0-0345337934
dc.identifier.scopus2-s2.0-0029823385
dc.identifier.urihttp://hdl.handle.net/11449/180595
dc.language.isopor
dc.relation.ispartofRevista Brasileira de Medicina
dc.relation.ispartofsjr0,101
dc.rights.accessRightsAcesso restritopt
dc.sourceScopus
dc.subjectantimicrobial drugs
dc.subjectbacterial sensitivity
dc.subjecthospital infection
dc.subjectamikacin
dc.subjectampicillin
dc.subjectantibiotic agent
dc.subjectaztreonam
dc.subjectcefalotin
dc.subjectcefoxitin
dc.subjectceftazidime
dc.subjectceftriaxone
dc.subjectciprofloxacin
dc.subjectgentamicin
dc.subjectimipenem
dc.subjectoxacillin
dc.subjectpefloxacin
dc.subjectvancomycin
dc.subjectantibiotic resistance
dc.subjectantibiotic sensitivity
dc.subjectcontrolled study
dc.subjectescherichia coli
dc.subjecthospital
dc.subjecthuman
dc.subjectklebsiella pneumoniae
dc.subjectminimum inhibitory concentration
dc.subjectnonhuman
dc.subjectpseudomonas aeruginosa
dc.subjectstaphylococcus aureus
dc.titleEstudo sobre a resistência aos antimicrobianos em bactérias isoladas de pacientes hospitalizados (Botucatu, 1988-1992)pt
dc.title.alternativeA survey of resistance to antimicrobial drugs in isolated bacterias from hospitalized patients (Botucatu, 1988-1992)en
dc.typeArtigopt
dspace.entity.typePublication
relation.isDepartmentOfPublicatione31a9b63-072c-4e5b-9812-9c0b621b4848
relation.isDepartmentOfPublication.latestForDiscoverye31a9b63-072c-4e5b-9812-9c0b621b4848
relation.isOrgUnitOfPublicationa3cdb24b-db92-40d9-b3af-2eacecf9f2ba
relation.isOrgUnitOfPublicationab63624f-c491-4ac7-bd2c-767f17ac838d
relation.isOrgUnitOfPublication.latestForDiscoverya3cdb24b-db92-40d9-b3af-2eacecf9f2ba
unesp.campusUniversidade Estadual Paulista (UNESP), Instituto de Biociências, Botucatupt
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatupt
unesp.departmentClínica Médica - FMBpt
unesp.departmentMicrobiologia e Imunologia - IBBpt

Arquivos